Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

A Study to Evaluate the Safety and Efficacy of Subcutaneously Administered REGN475(SAR164877) in Patients With Sciatic Pain

ClinicalTrials.gov ID: NCT00991172

Public ClinicalTrials.gov record NCT00991172. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 21, 2026, 2:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of Subcutaneously Administered REGN475 in Patients With Sciatic Pain

Study identification

NCT ID
NCT00991172
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Regeneron Pharmaceuticals
Industry
Enrollment
159 participants

Conditions and interventions

Conditions

Interventions

  • REGN475 Drug
  • Placebo Injection Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 31, 2009
Primary completion
Apr 30, 2010
Completion
Apr 30, 2010
Last update posted
Dec 7, 2011

2009 – 2010

United States locations

U.S. sites
30
U.S. states
18
U.S. cities
30
Facility City State ZIP Site status
Regeneron Investigational Site Birmingham Alabama
Regeneron Investigational Site Mobile Alabama
Regeneron Investigational Site Peoria Arizona
Regeneron Investigational Site Anaheim California
Regeneron Investigational Site Beverly Hills California
Regeneron Investigational Site National City California
Regeneron Investigational Site Santa Ana California
Regeneron Investigational Site Milford Connecticut
Regeneron Investigational Site Stamford Connecticut
Regeneron Investigational Site Clearwater Florida
Regeneron Investigational Site Hallandale Florida
Regeneron Investigational Site St. Petersburg Florida
Regeneron Investigational Site Tampa Florida
Regeneron Investigational Site West Palm Beach Florida
Regeneron Investigational Site Atlanta Georgia
Regeneron Investigational Site Sandy Springs Georgia
Regeneron Investigational Site Overland Park Kansas
Regeneron Investigational Site Rockville Maryland
Regeneron Investigational Site Kansas City Missouri
Regeneron Investigational Site Albuquerque New Mexico
Regeneron Investigational Site Raleigh North Carolina
Regeneron Investigational Site Cincinnati Ohio
Regeneron Investigational Site Duncansville Pennsylvania
Regeneron Investigational Site Tyrone Pennsylvania
Regeneron Investigational Site Warwick Rhode Island
Regeneron Investigational Site Greer South Carolina
Regeneron Investigational Site Memphis Tennessee
Regeneron Investigational Site El Paso Texas
Regeneron Investigational Site San Antonio Texas
Regeneron Invesitgational Site West Jordan Utah

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00991172, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 7, 2011 · Synced Jul 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00991172 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →